SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana is trending due to a sharp sell-off in the healthcare insurance sector, following the CMS's proposed nearly flat Medicare Advantage payment rates for 2027, which sparked widespread concern over future profitability. The community is actively debating whether this represents an overreaction and a buying opportunity at multi-year lows, or if it signals a more profound, structural challenge for companies heavily reliant on Medicare Advantage.

Mattel, Inc. engages in the ownership of children's and family entertainment franchises. It operates through the following segments: North America, International, and American Girl. The North America and International segments focus on marketing and selling toys and consumer products. The American Girl segment includes marketing, retailing, and publishing dedicated to its mission to help girls grow up with confidence and character. The company was founded by Elliot Handler, Ruth Handler, and Harold Matson in 1945 and is headquartered in El Segundo, CA.

Mattel, Inc.

Mattel is trending after a significant post-earnings decline driven by a profit miss and subdued outlook, igniting community discussions about whether the sharp drop presents a buying opportunity or signals deeper challenges, even with a substantial share repurchase program announced.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as its latest earnings report revealed stronger-than-expected profitability but a notable revenue miss, primarily impacted by a downturn in crypto trading activity. The community is actively debating if its "SuperApp" growth and new blockchain initiatives outweigh concerns over valuation and ongoing market sensitivity.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. It also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment offers products and services sold for applications within the data center, communication networks, and commercial and industrial markets in North America and Latin America. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks, and commercial or industrial markets throughout Greater China, Australia and New Zealand, Southeast Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Columbus, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings is trending following its Q4 earnings, where strong long-term guidance and robust organic orders growth are overshadowing a slight current quarter miss, reinforcing its position as a critical "picks and shovels" play in the expanding AI data center infrastructure. The community is actively discussing its sustained growth, pivotal role in cooling solutions, and potential S&P 500 index inclusion amidst market volatility.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as the successful unfurling of its BlueBird 6 satellite, the largest commercial communications array in low Earth orbit, coupled with recent FCC approval for US beta testing with major carriers, validates its direct-to-device technology. The community is buzzing with excitement over this significant de-risking event, anticipating potential short squeezes and a clearer path to commercialization and wider partnerships.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is actively discussed following its recent earnings report, which showcased significant revenue and origination growth alongside a leadership transition, yet the stock's reaction remains notably muted despite the strong operational beats. This has sparked intense community debate between those emphasizing its long-term AI lending potential and others pointing to broader fintech sector skepticism and persistent credit cycle concerns.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is trending due to a significant stock decline following a weaker-than-anticipated Q1 profit forecast, despite reporting strong Q4 results and authorizing a $1 billion share buyback. The community is sharply divided on whether the sell-off is an overreaction by algorithms or a valid concern about competitive pressures from rivals like Uber and the long-term impact of autonomous vehicle technology.

Oatly Group AB is a holding company, which focuses on developing expertise around oats, a global power crop with inherent properties suited for sustainability and human health. It operates through the following geographical segments: Europe & International, North America and Greater China. The company was founded by Björn Öste in 1994 and is headquartered in Malmö, Sweden.

Oatly Group AB - ADR

Oatly Group

Oatly is trending as the community keenly anticipates its upcoming earnings report, with discussions focusing on expectations for sustained profitability and robust growth guidance, alongside hopes for a strategic update on its China business.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is trending following its recent mixed earnings report, where an EPS miss was offset by stronger-than-expected revenue and global comparable sales driven by value initiatives and digital engagement. The community is actively debating if its value focus can sustain growth amidst ongoing high menu prices and broader economic pressures, despite management's cautious outlook on consumer spending.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as reports of its $2.25 billion acquisition of Kodiak Building Partners fuel community excitement, reinforced by a $3 billion financing from Apollo to accelerate its ambitious M&A roll-up strategy under CEO Brad Jacobs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Investors gear up for crucial jobs data and a slew of earnings reports from the likes of Shopify, QuantumScape, and Cisco, among others, today.</li><li>At 8:30 a.m. ET, the Bureau of Labor Statistics will release the delayed January Non-Farm Payrolls report.&nbsp;</li><li>In a setback for Nvidia, Chinese tech giant ByteDance is reportedly developing an artificial intelligence chip and is in talks with Samsung Electronics to manufacture it. &nbsp;</li></ul>U.S. stock futures were higher early Wednesday as investors gear up for the delayed January jobs report due later today and digested a slew of earnings reports.As of 3:10 a.m. ET on Wednesday, Dow, S&amp;P 500, and Nasdaq futures were up 0.1%, and Russell 2000 futures were higher by 0.2%.&nbsp;&nbsp;Meanwhile, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has remained ‘bearish’, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has fallen to ‘extremely bearish’ from ‘bearish’ a day ago amid high message volumes.&nbsp;Trending Stocks To WatchNvidia (NVDA):&nbsp;In a setback for Nvidia, Chinese tech giant ByteDance is reportedly developing an artificial intelligence chip and is in talks with Samsung Electronics to manufacture it.Warner Bros. Discovery deal (WBD, NFLX, PSKY):&nbsp;Activist investor Ancora Holdings has built a nearly $200 million stake in the media conglomerate and is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/warner-bros-netflix-deal-activist-reportedly-builds-200m-stake-in-wbd/cZbCCUoR4pv">reportedly</a> planning to nudge it toward Paramount Skydance’s acquisition offer and not Netflix.Moderna (MRNA): Faces headwinds after receiving a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-moderna-stock-tumble-after-hours-today/cZbCDktR4pA">"Refusal-to-File" letter</a> from the FDA regarding its investigational seasonal flu vaccine, mRNA-1010.Robinhood (HOOD): Shares fell in overnight trade as a miss in cryptocurrency revenue overshadowed record options and equities trading volumes.AST SpaceMobile (ASTS): A bright spot in the pre-market, the company successfully unfolded its BlueBird 6 satellite. It was also named as one of the three largest additions to the MSCI World Index.Ford Motor (F): In the spotlight after it reported a steady 2026 profit forecast, though the automaker notably fell behind China’s&nbsp;BYD in global sales for the first time.And watch out for&nbsp;Idea Acquisition Corp (IACOU), a new AI-focused SPAC, which begins trading on the Nasdaq today.Other tickers trending on Stocktwits at the time of writing included Mattel (MAT), Astera Labs (ALAB), Roblox (RBLX), and Carvana (CVNA), among others.&nbsp;Other Catalysts To WatchOn the economic front, the 8:30 am ET Jobs Report is the primary focus. Investors will also be watching for commentary from Kansas City Fed President Schmid’s speech at 10:10 am ET. On the earnings radar, investors will also be watching for the quarterly reports from Shopify (SHOP), Kraft Heinz (KHC), Unity Software (U), Cisco (CSCO), QuantumScape (QS), and MGM Resorts, among others.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Rise Ahead Of Delayed Jobs Data: Why NVDA, WBD, HOOD, MRNA, ASTS Are On Traders' Radar Today

Retail chatter on Stocktwits shows that sentiment remains deeply bearish on SPY and QQQ. 

Equity

Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of "Reduce" from Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) have been given a consensus recommendation of "Reduce" by the eighteen ratings firms that are covering the firm, MarketBeat.com reports. Five...

<ul class="summary-bullets"><li>The regulator said the Phase 3 study comparator did not reflect the “best-available standard of care,” though it raised no safety or efficacy concerns.</li><li>Moderna said the refusal conflicts with prior FDA guidance that allowed the comparator.</li><li>CEO Stephane Bancel will seek clarity through a requested Type A meeting.</li></ul>Shares of Moderna, Inc. (MRNA) fell about 9% in after-hours trading on Tuesday after the company said U.S. regulators declined to accept its application for review of its experimental seasonal influenza vaccine, marking another regulatory setback for the vaccine maker.In the regular session,&nbsp;<a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> rose 0.1% to $41.99. The regulatory setback also lifted shares of rival Novavax, which is developing a protein-based seasonal influenza vaccine candidate, with the stock rising more than 1% in after-hours trading.<h2 class="st-heading-2">FDA Rejects Moderna Flu Vaccine Filing</h2>Moderna said the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) issued a refusal-to-file letter for the biologics license application (BLA) of its investigational flu vaccine, mRNA-1010, and will not initiate a review, despite the company using a priority review voucher.The letter said the application lacked an “adequate and well-controlled” study using a comparator reflecting the “best-available standard of care,” and did not raise any safety or efficacy concerns.The BLA includes two positive Phase 3 studies enrolling 43,808 participants. One showed a stronger immune response and a favorable safety profile compared with a high-dose flu shot in adults aged 65 and older, while the other showed higher effectiveness than a standard-dose vaccine in adults aged 50 and older. Moderna said the FDA reviewed and cleared both trial designs before the studies began.The decision was signed by Vinay Prasad, who is also known for halting broader access to Sarepta Therapeutics’ gene therapy Elevidys, drawing backlash over access to the only approved treatment for Duchenne muscular dystrophy.<h2 class="st-heading-2">Moderna Flags Inconsistency In FDA Feedback</h2>Moderna said the refusal conflicted with earlier written guidance from the FDA’s CBER. In April 2024, regulators said using a licensed standard-dose influenza vaccine as the comparator would be acceptable, while recommending a high-dose or an adjuvanted vaccine for participants&nbsp;aged 65 and older. The company said no objections or clinical holds were raised after the Phase 3 protocol was submitted or before the trial began in September 2024.After the Phase 3 study met all pre-specified endpoints, Moderna said it provided additional comparator analyses requested during an August 2025 pre-submission meeting, including data from a separate Phase 3 trial comparing a licensed high-dose flu vaccine with a comparator. Moderna said the FDA did not signal it would refuse to review the application.CEO Stephane Bancel said the decision&nbsp;was based on no safety or efficacy issues and that the company would seek clarity on the path forward.<h2 class="st-heading-2">Moderna Seeks Type A FDA Meeting</h2>Moderna said it has requested a Type A meeting with CBER. The company said mRNA-1010 has been accepted for review in the European Union, Canada and Australia, with additional country submissions planned for 2026. It expects the earliest potential approvals outside the U.S. in late 2026 or early 2027 and said the FDA decision will not affect its 2026 financial guidance.<h2 class="st-heading-2">Regulatory Backdrop Weighs On Vaccine Makers</h2>The FDA decision adds to regulatory uncertainty facing vaccine manufacturers in the U.S. Last month, Bancel told&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-01-22/moderna-mrna-curbs-investment-in-vaccine-trials-due-to-us-backlash">Bloomberg</a> at the World Economic Forum in Davos that Moderna does not plan to invest in new late-stage vaccine trials without clearer access to the U.S. market, citing regulatory delays and reduced support for immunization programs.In December, a leaked internal email from Prasad surfaced, asserting that COVID-19 vaccines were linked to at least 10 pediatric deaths, a claim experts said lacked supporting data. Moderna has been seeking to diversify beyond its COVID-19 vaccines and is focusing on personalized cancer vaccines, while also looking for external funding partners to advance certain late-stage vaccine programs.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for MRNA was ‘bearish’ amid ‘low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_png_b80d531229.webp" alt="mrna ss.png" width="969" height="143"><figcaption>MRNA sentiment and message volume as of February 10 | Source: Stocktwits</figcaption></figure>One bearish user said, “So glad I sold at $49 this time round. This is going to struggle to stay solvent soon.”<stembedurl>https://stocktwits.com/TopazFrenzy/message/644621591</stembedurl>Another user called the company a “Great short!” and expects the stock to trade in the range of $20-$28.<stembedurl>https://stocktwits.com/Tradebub/message/644623819</stembedurl>MRNA stock has risen 32% over the past 12 months.See Also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mrna-vs-nvax-which-vaccine-stock-is-wall-street-more-bullish-on-right-now/cmUzkZbR4QI">MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Why Did Moderna Stock Tumble Nearly 10% After Hours Today?

The FDA’s CBER issued a refusal-to-file letter for Moderna’s flu vaccine mRNA-1010.

Moderna says FDA refuses its application for new mRNA flu vaccine

The U.S. Food and Drug Administration is refusing to consider Moderna's application for a new flu vaccine made with mRNA technology...

Moderna says FDA refuses to review its application for experimental flu shot

Moderna said the move is inconsistent with previous feedback from the FDA on the experimental influenza shot, called mRNA-1010...

Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards?

VRTX is set to report Q4 results amid strong Trikafta demand. Alyftrek launches are gaining traction while investors are eyeing Casgevy and Journavx sales.

Should You Buy Moderna Before Feb. 13?

Key PointsModerna's shares have performed well this year, driven by clinical and regulatory progress...

Moderna (MRNA) Laps the Stock Market: Here's Why

In the latest trading session, Moderna (MRNA) closed at $41.95, marking a +2.29% move from the previous day.

Top Biotech Stocks To Add to Your Watchlist - February 9th

argenex, Vertex Pharmaceuticals, Danaher, Moderna, and Medpace are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded...

Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?

Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $SHOP earnings on Wednesday?

Stocktwits

Shopify Inc

Stocktwits Polls

The US FDA refused to review the company's innovative mRNA flu vaccine due to clinical trial design concerns, causing a significant share price drop.

Shares saw a rapid decline, notably falling from $45 to $37 in one day after the FDA news, fueling both short-selling interest and recovery speculation.

Current Price	$42.00
Prev Close	$41.95
Open	$42.87
Dividend Yield	0.00%
50-Day Moving Average	$35.43
Beta	1.30
Avg. Volume	14.75M
PE Ratio	-5.20

52-Week High	$55.20
52-Week Low	$22.28
Market Capitalization	$16.39B
EPS (Annual)	-$9.27
Price to Book	1.76
Revenue Per Employee	$557,931.03

MRNA
Moderna Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRNA News

MRNAModerna Inc